ArticleJournal of thoracic disease2025
Geospatial analysis as a tool for identification of potential targetable regions for lung cancer screening interventions in Massachusetts.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Geospatial analysis as a tool for identification of potential targetable regions for lung cancer screening interventions in Massachusetts.Journal of thoracic disease · 2026Article
- Mapping the gaps: a geospatial approach to equity in lung cancer screening.Journal of thoracic disease · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Racial and socioeconomic disparities in lung cancer are well documented. Given the benefits of surgery and targeted therapies for early-stage disease, there is a need to increase screening participation of high-risk groups to improve survival. Yet, best practices for ascertaining which groups would benefit are lacking. The aims of this study were to demonstrate an association between zip code and stage at diagnosis of lung cancer as well as an association between zip code and age at diagnosis of lung cancer in Massachusetts patients. Methods: To identify such populations in Massachusetts, patients diagnosed with lung carcinoma from 2004 to 2020 were identified utilizing the Massachusetts Cancer Registry (n=72,559). Zip code-level demographic information, median household income, and percentage of residents without a high school diploma were obtained from census data. Geospatial analysis using ArcGISPro identified spatial trends in lung cancer incidence and patient characteristics. Results: Average age at diagnosis was 69.4 (±10.2) years old and the majority were White (95.9%) and female (53.8%). Many patients had distant (47.6%) spread at diagnosis, compared to regional (16.3%) or local disease (36.1%). Median household income and educational attainment were correlated with late-to-early-stage prevalence ratio for lung cancer (P<0.05). Higher proportions of Black residents in a zip code correlated with an increased rate of late-stage lung cancer cases in young patients (≤55 years; P<0.05) and further demonstrated geographic trends toward higher incidence of late-stage disease, lower educational attainment, and lower income. Conclusions: These results demonstrate the utility of geospatial analysis to detect trends in the incidence of late-stage lung cancer relating to race, age, education, and socioeconomic factors. Importantly, these results can direct location preferences for early intervention efforts including patient/provider education and mobile lung cancer screening clinics, particularly in neighborhoods with lower income and education levels (248/250).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.